Swedish clinical-stage pharmaceutical company Vicore Pharma Holding AB (STO:VICO) announced on Tuesday that Japan's Ministry of Health, Labor and Welfare has granted Orphan Drug designation to buloxibutid for the treatment of idiopathic pulmonary fibrosis (IPF).
Buloxibutid is a first-in-class angiotensin II type 2 receptor agonist that promotes alveolar repair, resolves fibrosis, and supports pulmonary vascular function.
In February 2024, Vicore entered an exclusive licensing agreement with Nippon Shinyaku to develop and commercialise buloxibutid in Japan. Orphan designation provides incentives such as reduced consultation and review fees and extended market exclusivity upon approval.
Buloxibutid previously received Orphan Drug designation from the European Commission in 2016 and the US FDA in 2017, and Fast Track designation from the FDA in 2025.
The therapy is currently being evaluated in the global Phase 2b ASPIRE trial for IPF.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval